Safety and Immunogenicity of a Live, Attenuated Rotavirus Vaccine (RotaTeq) in HIV-1 Infected and Uninfected Children Born to HIV-1-Infected Mothers

Trial Profile

Safety and Immunogenicity of a Live, Attenuated Rotavirus Vaccine (RotaTeq) in HIV-1 Infected and Uninfected Children Born to HIV-1-Infected Mothers

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Rotavirus W179-9 vaccine (Primary)
  • Indications Rotavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2017 Results of a secondary analysis (n=89) associating HIV status and rotavirus vaccine with B and T cell subsets, presented at the 24th Conference on Retroviruses and Opportunistic Infections
    • 17 Feb 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top